FDA approval expected for expanded use of Zevalin

09/4/2009 | Reuters

Analysts are expecting the FDA to approve the use of Spectrum Pharmaceuticals' cancer drug Zevalin as a first-line treatment for non-Hodgkin's lymphoma. The drug currently is approved as treatment for relapsed or refractory NHL. The FDA is set to hand down its decision on Monday.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA